Vidhya Murthy

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial

Andrew H. Wei, Pau Montesinos, Vladimir Ivanov et al. · Blood · 2020 · 756 citations · Full text

Medicine, Oncology, Pharmacology +9

Molecular MRD is strongly prognostic in patients with <i>NPM1</i>-mutated AML receiving venetoclax-based nonintensive therapy

Jad Othman, Ing Soo Tiong, Jenny O’Nions et al. · Blood · 2023 · 65 citations · Full text

Medicine, Hematology, Oncology +14

6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy

Andrew H. Wei, Panayiotis Panayiotidis, Pau Montesinos et al. · Blood Cancer Journal · 2021 · 38 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy

Andrew H. Wei, Panayiotis Panayiotidis, Pau Montesinos et al. · Blood · 2022 · 38 citations · Full text

Medicine, Oncology, Chemotherapy +7

Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS

Jad Othman, Ho Pui Jeff Lam, Sarah Leong et al. · Blood Neoplasia · 2024 · 36 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11